EquityBulls

Latest News

Keywords Selected: Lupin

Research

Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg - Pegfilgrastim-unne
Lupin Foundation Earns CRISIL's Highest VO 1A Rating for Excellence in Social Responsibility
Lupin Ltd receives 7 observations from USFDA for Goa manufacturing facility
Lupin announces closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facility with No Observations
Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S.
Lupin Establishes a New Global Standard in Sustainable Pharma with an S&P Global ESG Score of 91
Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility
Lupin Manufacturing Solutions Unveils Dedicated Oncology Block at Vizag, India
Lupin Bioresearch Center receives Zero Observations from U.S. FDA after Successful Inspection and Assessment
Lupin Digital Health Launches VITALYFE™
Lupin Launches Authorized Generic Version of Ravicti® in the United States
Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
Lupin gets one observation from USFDA for Somerset, New Jersey manufacturing facility
Lupin unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
Lupin Launches Liraglutide Injection in the United States
Lupin Launches Rivaroxaban for Oral Suspension in the United States
Lupin receives approval from U.S. FDA for Rivaroxaban for Oral Suspension
Lupin Strengthens its Global Specialty Ophthalmology Business with acquisition of VISUfarma from GHO Capital
Lupin gets 4 observations from USFDA from PAI at Pune Biotech facility
Lupin receives approval from U.S. FDA for Lenalidomide Capsules
Lupin receives 6 observations from USFDA for Nagpur Injectable facility
USFDA conducts product specific pre-approval inspection at Lupin Ltd's Aurangabad facility
Lupin receives U.S. FDA approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity
Lupin launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity